New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
04:54 EDTINOInovio's HBV therapeutic vaccine generated strong T cell responses
Inovio Pharmaceuticals announced that its synthetic hepatitis B, or HBV, therapeutic vaccine generated strong T cell responses that eliminated targeted liver cells in mice. This data points to the DNA vaccine's potential to clear HBV infection and thereby prevent liver cancer in humans, an encouraging development given that nearly one-third of the world's population is infected with hepatitis B, with 400 million at risk of developing liver cancer. In the study, Inovio researchers and collaborators constructed a DNA vaccine encoding an HBV core antigen using the SynCon vaccine technology and administered it via Inovio's proprietary electroporation-based delivery technology. Researchers observed that the vaccine induced strong "killer" T cells in an animal model. Importantly, those killer T cells, while found systemically, were also present in the liver and provided clearance of HBV antigen-expressing liver cells without inducing liver damage. The company is also investigating additional HBV antigens to develop a multi-component vaccine that can provide the host immune system multiple targets to clear the hepatitis B virus and infected liver cells.
News For INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2015
08:08 EDTINOInovio says HPV Immunotherapy activates robust in vivo T cell responses
Inovio Pharmaceuticals announced preliminary data showing that its INO-3112 DNA-based immunotherapy generated strong CD8+ T cell responses in 3 of 4 patients with head and neck cancer associated with human papillomavirus (HPV) types 16 and 18. INO-3112, an active immunotherapy that targets HPV 16 and 18 and simultaneously expresses IL-12, is designed to activate in vivo immune responses to antigens from high risk HPV types and eliminate precancerous and cancerous cells displaying these antigens. The magnitude and characteristics of these interim immune response data mirror immune responses previously observed in human studies of VGX-3100 for HPV-associated cervical dysplasia; in a placebo-controlled phase II study, strong T cell immune responses were positively correlated with achievement of primary and secondary efficacy endpoints, the company said. The data, which are T cell measurements from the first four treated patients of this phase I/IIa study, are being presented today at the World Vaccine Congress 2015 by Inovio COO, Dr. Niranjan Sardesai.
April 8, 2015
19:46 EDTINOOn The Fly: After Hours Movers
UP AFTER EARNINGS: Apogee (APOG), up 6.4%... Pier 1 Imports (PIR), up 4.4%. ALSO HIGHER: Inovio Pharmaceuticals (INO), up 5.6% after being selected by DARPA to lead $45M Ebola prevention program. DOWN AFTER EARNINGS: Alcoa (AA), down 3.5%... Bed Bath & Beyond (BBBY), down 3.5%. ALSO LOWER: Zynga (ZNGA), down 10.3% after announcing CEO transition... Memorial Production (MEMP), down 2.9% after filing to sell 4.6M common units owned by MRD Holdco... Regulus (RGLS), down 2.2% after filing to sell 3.3M shares for Isis Pharmaceuticals.
09:20 EDTINOOn The Fly: Pre-market Movers
Subscribe for More Information
06:06 EDTINOInovio selected by DARPA to lead $45M Ebola prevention program
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use